Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2 by Okubo, Yoshiaki et al.
 
Homogeneous Expansion of Human T-Regulatory Cells Via
Tumor Necrosis Factor Receptor 2
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Okubo, Yoshiaki, Toshiyuki Mera, Limei Wang, and Denise L.
Faustman. 2013. “Homogeneous Expansion of Human T-
Regulatory Cells Via Tumor Necrosis Factor Receptor 2.”
Scientific Reports 3 (1): 3153. doi:10.1038/srep03153.
http://dx.doi.org/10.1038/srep03153.
Published Version doi:10.1038/srep03153
Accessed February 19, 2015 2:54:05 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879186
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAHomogeneous Expansion of Human
T-Regulatory Cells Via Tumor Necrosis
Factor Receptor 2
Yoshiaki Okubo, Toshiyuki Mera, Limei Wang & Denise L. Faustman
Immunobiology Laboratory, Massachusetts General Hospital and Harvard Medical School, Rm 3602, MGH-East, Bldg 149, 13
th
Street, Boston, MA 02129.
T-regulatory cells (Tregs) are a rare lymphocyte subtype that shows promise for treating infectious disease,
allergy, graft-versus-host disease, autoimmunity, and asthma. Clinical applications of Tregs have not been
fully realized because standard methods of expansion ex vivo produce heterogeneous progeny consisting of
mixed populations of CD4 1 T cells. Heterogeneous progeny are risky for human clinical trials and face
significant regulatory hurdles. With the goal of producing homogeneous Tregs, we developed a novel
expansion protocol targeting tumor necrosis factor receptors (TNFR) on Tregs.I nin vitro studies, a TNFR2
agonist was found superior to standard methods in proliferating human Tregs into a phenotypically
homogeneous population consisting of 14 cell surface markers. The TNFR2 agonist-expanded Tregs also
were functionally superior in suppressing a key Treg target cell, cytotoxic T-lymphocytes. Targeting the
TNFR2 receptor during ex vivo expansion is a new means for producing homogeneous and potent human
Tregs for clinical opportunities.
T
- regulatory cells (Tregs) are a small subset of T-lymphocytes with diverse clinical applications in trans-
plantation, allergy, infectious diseases, GVHD, autoimmunity, cancer, among others
1–10. One fundamental
problem stymieing their clinical development is their relative paucity: naturally occurring Tregs constitute
only 1–5% of total CD41 T cells in blood, and remain largely dormant until activated. Their expansion is
therefore crucial for harvesting sufficient quantities to investigate their roles in basic biology and clinical medi-
cine
11,12. Standard methods of Treg expansion
13–29 are conducted ex vivo for reinfusion into patients because the
expansion agents are too toxic for in vivo administration. Four expansion agents are commonly used alone or in
various combinations: IL-2, anti-CD3, anti-CD3 plus anti-CD28, and rapamycin. However, those standard
agents are problematic because they produce heterogeneous progeny consisting of phenotypically and function-
ally mixed populations of CD4
1 T cells. Heterogeneous CD41 T cell populations hold risk because they are
capable of releasing pro-inflammatory cytokines, and they possess cells with diverse, sometimes antagonistic
functions. Heterogeneous populations are also deemed by regulatory agencies as impure and irreproducible,
impeding the advance of human clinical trials. Thus a major research goal has been to find new ligands to
selectively expand Tregs into homogeneous progeny.
In humans, Tregs are defined by co-expression of CD41 and high expression of the interleukin-2 (IL-2)
receptor alpha chain CD25
hi.T regs also feature inducible levels of intracellular transcription factor forkhead
box P3 (FOXP3)
30,31. Here we chose to focus on TNF and its receptors on Tregs. While animal studies indicate
that TNF induces proliferation of Tregs, the evidence in humans, both in vivo and in vitro, is conflicting and the
topic for review articles attempting to explain the contradictory literature
32,33. It has been speculated that the
conflicting findings could be due in part to the manufacturing problems with TNF and its tendency in culture to
aggregateintodifferentcomplexes,perhapswithdifferentsignalingconsequences
34.AlsoTNFhastworeceptors,
TNFR1 and TNFR2, each of which controls different signaling pathways. Unlike TNFR1, which has ubiquitous
cellular expression, TNFR2 is expressed in a more limited manner, restricted primarily to subpopulations of T
cells,endothelialcells,andneurons
35.ResearchinprimatessuggeststhatTNFR2-specificligandsarelikelytohave
minimal systemic toxicity because of TNFR2’s restricted cellular distribution
36. Naturally occurring Tregs appear
to express TNFR2 at a higher density than TNFR1
37–39. These features might make human TNFR2 an advant-
ageous molecular target on Tregs.
We began by examining whether soluble TNF could expand human Tregs in vitro. Once we determined that
TNF could successfully expand them, we then used monoclonal antibodies to tease apart the roles of TNFR1 and
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SCIENTIFIC REPORTS | 3 : 3153 | DOI: 10.1038/srep03153 1TNFR2. We studied the newly screened antibodies’ effects on Treg
proliferation, signaling, phenotype, and function bymultiple in vitro
assaysusingisolatedfreshhumanCD4Tcellsfromover500donors.
In these experiments, our purpose was to compare performance of
our TNF antibodies against standard methods of Treg expansion.
Once we found that one TNFR2 monoclonal antibody could expand
Tregs into a homogeneous population with potent functional capa-
city, we sought to extend our findings to humans with a small ran-
domized, controlled clinical trial with the TNF-inducer Bacillus
Calmette-Guerin (BCG), an approved drug.
Results
Functional effects of TNF and TNFR monoclonal antibodies on
Tregs.Thepurposeofthisstudywastousefourstandardmethodsfor
Treg expansion and examine the effects of adding TNF or TNF re-
ceptorantibodiestotheculture.Wesoughttoimprovethepurityand
potencyoftheexpandedTregs,perhapscreatingapreparationofcells
moresuitableforhumantrials.Thefourexpansionprotocolsusedas
a screening tool for monoclonal antibodies were tests with human T
cellswitha)IL-2expansion,b)anti-CD3expansion,c)anti-CD3and
anti-CD28 expansion, and d) anti-CD3 and anti-CD28 expansion
with rapamycin, all with the absence or addition of TNF and newly
screened or applied TNFR receptor monoclonal antibodies.
IL-2is important forTreginduction and maintenance inmice
4.To
gain some early appreciation of the human version of this cytokine
on human cultured T lymphocytes, we first cultured freshly isolated
human CD41 cells from 14 human subjects only with TNF or IL-2
for16 hours(Fig.1).WhilefindingnoinductionofTregs,assessedby
inducible FOXP3, we observed a significant increase in Tregs after
adding IL-2 with TNF. This percentage increase in the numbers of
Tregs was due to greater numbers of Tregs. Co-incubation of TNF and
IL-2producedasignificant increaseinTregsoverIL-2alone(Fig.1a).
By flow cytometry, TNF and IL-2 co-incubation also increased the
numberofCD41CD25
hiFOXP3 cellsincultured humancellsfrom
blood (Fig. 1b).
WefirstexploredwhetherbothTNFreceptorswereneededforthe
TNF effect. Because TNF signals through two receptors, we studied
eachTNFRreceptorinisolationusingnewlyproducedandcommer-
cially available monoclonal antibody ligands to TNFR1 and TNFR2.
Unlike cytokines that can be difficult to manufacture and have vary-
ing solubility, antibodies have excellent solubility. In freshly isolated
CD41cells,weexaminedexpression levels ofeach TNFRinrelation
to CD251 expression. TNFR1 expression on CD41 cells, regardless
of CD251 expression levels, was unchanged using flow cytometry
(Fig. 2a, middle panel), whereas TNFR2 preferentially expressed
CD4
1CD25
hi Tregs by nearly a factor of 10 (Fig. 2a, right panel).
This confirms earlier studies that TNFR2 is more densely expressed
on Tregs
37–39.
ScreeningallavailableTNFR1andTNFR2monoclonalantibodies
(mAbs) on isolated CD41 cells sampled from fresh human blood
enabled selective study of each TNF receptor, unlike studying TNF,
which acts through both receptors and can have manufacturing and
solubility problems stemming from the use of E. Coli and yeast
systems. Although most of the newly produced and commercially
available TNFR1 or TNFR2 mAbs failed to induce or suppress
FOXP31 Tregs after stimulation by presence of IL-2 for 16 hours
(Supplementary Figs. 1, 2), we eventually identified two TNFR2
mAbs with significant, yet opposing, effects on FOXP3 induction
(Fig. 2b). Studying freshly cultured cells from 10 subjects, one
TNFR2 antibody significantly induced FOXP3 expression in
CD41 human T cells and expanded these cells in culture (which
we designated the ‘‘TNFR2 agonist’’), whereas the other TNFR2
monoclonal had no benefit in augmenting intracellular FOXP3
expression and with these culture conditions prevented CD4 T cell
proliferation (which we designated the ‘‘TNFR2 antagonist’’)
(Fig. 2b). The reason for the increases in FOXP3 with the newly
identified TNFR2 agonist was almost entirely secondary to expan-
sion of absolute Treg cellnumbers. There was no statistical difference
between IL-2 alone and IL-2 plus TNFR2 antagonist in Treg cell
numbers.
Having identified two functionally opposing TNFR2 mAbs, we
measuredtheireffectsonisolatedCD41Tcellsbyexaminingdown-
stream mRNA expression in signaling proteins specific to TNF
receptor activation. After either 30 minutes or 24 hour stimulation
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Figure 1 | Human CD41 T cells cultured with TNF and/or IL-2 and measured for FOXP3 expression. (a) In freshly isolated CD41 cells from human
blood, TNF alone does not induce FOXP3 in culture, but does induce it to higher levels when co-incubated with IL-2, compared to IL-2 alone.
(b)ArepresentativeflowhistogramconfirmsgreaterintracellularinductionofFOXP3inCD41CD25
hiTregsafterco-incubationwithTNFandIL-2than
with IL-2 alone. The data in (a) are from 14 subjects (left panel) and 10 subjects (right panel). Figures in flow diagrams are %. (***P , 0.001, by
paired t-test).
www.nature.com/scientificreports
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Figure 2 | TNFR2 agonist- versus antagonist-treated Tregs and opposing effects in vitro. (a)TNFR2 is preferentially expressed on CD41CD25
hiTcells
(b)oneTNFR2antibodyinduced thenumbers ofFOXP3,actingasan agonist,andtheotherTNFR2antibody suppressed thenumbers ofFOXP3,acting
asantagonist.(c)Inasignalingpathwayassay,purified CD41cells,incubatedwithIL-2,theTNFR2agonistandantagonist triggerdifferencesinrelative
downstream expression of mRNA, especially in signaling proteins TRAF2, TRAF3 and apoptosis inhibitor cIAP2 that are preferentially induced by
TNFR2 agonism. Data represented are means 6 SEM from 4 subjects. (d) TNFR2 agonist triggers greater % increase in proliferation in samples from 6
subjects measured by flow cytometry (left panel) and with CFSE measurements (right panels), and representative results from a typical experiment are
presented with CFSE measurements (right panels). The numbers in a bar represent the percentage of cells that enter division. The TNFR2 antagonist
suppresses CD41proliferation (left panel) andinhibits expansion measured by CFSEdilution (right panel). (*P ,0.05 or **P ,0.01, by paired t-test).
www.nature.com/scientificreports
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Figure 3 | TNFR2agonistversusantagonistonexpansionofTregpopulation.(a)ProtocolforpurifyingCD41CD25
hicellsfromCD41cellsfromfresh
bloodandexpandingfor16daysbyincubationin96wellround-bottomplate(23104 cells/well)withanti-CD3andanti-CD28antibodies,humanIL-2,
and rapamycin. (b) Representative CD25 and FOXP3 flow diagrams of CD41 cells before versus after CD25
hi purification and expansion, indicating
purity of populations. (c) Cell counts of purified Tregs, by treatment group, reveal that TNFR2 agonist induced more expansion than any other group.
(**P , 0.01, by paired t-test.) The TNFR2 antagonist suppresses expansion versus standard treatment. Data in (c) are samples from 10 subjects.
www.nature.com/scientificreports
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significantly different. The TNFR2 agonist stimulated expression of
TNF, TRAF2, TRAF3, BIRC3 (cIAP2) and FOXP3 (24 hour data
shown). In contrast, the TNFR2 antagonist stimulated expression
of cIAP1, but not TRAF2, TRAF3 or FOXP3 (Fig. 2c). This was
not only confirmed in four human subjects (Fig. 2c), but also with
32 additional human subjects with the TNFR2 agonist and an addi-
tional 8 subjects with the TNFR2 antagonist. Distinct intracellular
signaling was triggered by the newly identified antibody agonist and
the antibody antagonist to TNFR2 (Fig. S2b).
The effectsof theTNFR2agonist andantagonist werealsostudied
on purified human CD41 T cells co-cultured with anti-CD3. When
CD41 proliferation was studied with anti-CD3 combined with the
TNFR2 agonist, the highest degree of proliferation occurred. This
absolute expansion and proliferation was almost exclusively (85%)
due to the expansion of Tregs. In contrast, the TNFR2 antagonist
suppressed CD41 proliferation relative to the control, anti-CD3
alone, and relative to anti-CD3 1 TNFR2 antagonist (Fig. 2d, left-
mostpanel).Thesamefindingswereobservedafter4daysbydirectly
measuring CD41 proliferation by flow cytometry and measuring
CD41 proliferation by CFSE dilution (Fig. 2d, three right-most
panels).
DespitehighexpressionofTNFR2onTregs,someTNFR2express-
ionisalsoobservableonCD41TcellsthatarenottrueTregsbecause
they only express intermediate levels of CD25, i.e., CD4
1CD25
mid
cells. We therefore studied the impact of overnight incubation on
CD25
midcellsubpopulationsofIL-2alone,IL-2andTNF,orIL-2and
TNFR2 agonist, or IL-2 and TNFR2 antagonist. We found a rise in
the proportion of CD25
hiFOXP3
2 cells similar to effector cells with
IL-2 and TNF stimulation alone, or IL-2 and TNFR2 agonist alone
(data not shown). However, we observed suppression with IL-2 and
TNFR2 antagonist relative to the other three groups. Therefore the
TNFR2 agonist and antagonist, studied by the same assay, showed
opposing effects on the same CD25
1FOXP3- cell population.
We separated fresh human blood to obtain pure CD41 and
CD25
hi co-expressing Tregs (Fig. 3). We purified and expanded these
Tregs in vitro using another standard method of Treg expansion, anti-
CD3 plus anti-CD28 plus IL-2 for 16 days with or without TNF,
TNFR2 antagonist, or TNFR2 agonist (Fig. 3a), then rested them
overnight before counting. We added rapamycin (until day 7)
becauseitselectively expands the highestnumber of Tregswithgreat-
est capacity for suppressing CD81 cells
40–43. This process success-
fully produced CD41CD25
hi Tregs (Fig. 3b). We assessed Treg
expansion by treatment group: standard treatment, treatment with
TNF, TNFR2 agonist, or TNFR2 antagonist. The TNFR2 agonist
outperformed every other group, expanding Treg numbers at least
twofold higher than standard treatment or antagonist treatment
(Fig. 3c). Because rapamycin is known to inhibit proliferation, we
examined the effects of treatment without rapamycin, yet found
similarly opposing effects between agonist versus antagonist treat-
ment, albeit at smaller mean absolute values (Supplementary Fig. 3).
Theyieldsofexpandedcellstendedtobelesswithoutrapamycin,but
the agonist still expanded Tregs.
TNFR2 agonist expansion and homogeneity of Tregs. We next
investigated whether Tregs, treated by TNFR2 agonist in vitro,
possessed more homogeneous Treg cell surface markers than those
givenstandardtreatmentorantagonisttreatment.Comparingatfirst
thephenotypesfor7cellsurfacemarkers,alltreatmentgroupshighly
expressed Treg signature markers FOXP3 and CD25 (Fig. 4a). The
expression levels of FOXP3 were similar to levels before treatment
(Supplementary Fig. 4, 5). Nearly 100% of expanded CD25
hi Tregs in
each group were positive for CTLA4, TNFR2, CD62L, Fas, and
negative for CD127 (Fig. 4a). Comparing the surface phenotypes
for the next 7 cell surface markers, the TNFR2 agonist produced
the most homogeneous cells for such markers as HLA-DR, ICOS,
CD45RO, CXCR3, CCR4, CCR6 and CCR7 (Fig. 4b). Surface mar-
kers, such as HLA-DR, ICOS, CD45RO and chemokine receptors,
weredifferentiallyexpressedbetweentheagonistvs.antagonisttreat-
ment (Fig. 4b,c). Similar results were observed in Tregs expanded
without rapamycin (Supplementary Fig. 4). Tregs expanded by
TNFR2 agonist—relative to most other comparator groups, espe-
cially the TNFR2 antagonist—yielded a surprisingly homogeneous
population of cells with this phenotype: CD4
1CD25
highFOXP3
1
CTLA4
1TNFR2
1CD127
2CD62L
1Fas
1HLA-DR
1CD45RO
1CCR5
2
CCR6
2CCR7
2CXCR3
2ICOS
2. The mean fluorescence intensity
(MFI), a direct measure of the average density of the protein per
cell, similarly revealed that for most surface markers, the TNFR2-
agonist treated cells were more homogeneous than those produced
by standard treatment or TNFR2 antagonist treatment (Supple-
mentary Fig. 6). Further investigation should determine whether
these expanded cells maintain phenotypic homogeneity over time.
Before treatment, Treg markers were more heterogeneous (Supple-
mentary Fig. 5). In vitro studies of mixed Treg populations, which
include CD45RO
1FOXP3
low T cells, produce pro-inflammatory
cytokines. This particular phenotype is found in up to 50% of
FOXP31 T cells.
One of the most upregulated markers by TNFR2 agonist-treated
Tregs was HLA-DR, which is reported to have higher suppressive
activity against CD8 T1 cells, suggestive of an effector Treg
44.I n
contrast to HLA-DR, all four chemokine receptors were strongly
down-regulated. Although the lack of chemokine receptors might
result in failure to migrate to the site of inflammation, another hom-
ing receptor, CD62L, which was highly expressed in all treatment
groups (Fig. 4), is crucial for entering the site of pathogenic T cell
presence in acute GVHD. The fact that agonist-treated Tregs were
CD45RO1 and CCR72 and displayed significantly higher express-
ion levels of Fas, measured by MFI (Supplementary Fig. 6), contri-
butes to the view that they are activated effector Tregs.
TNFR2 agonist-treated Tregs and CD81 suppression. One key
function of Tregs, especially in autoimmunity, is to suppress the
function of autoreactive cytotoxic CD81 T cells. We assessed this
functional capacity by mixing Tregs from each treatment group with
CFSE-stained autologous PBMC, after having stimulated them with
anti-CD3mAb and IL-2 for 4 days. Autologous CD81 T cells, the
responder cells, were tested for suppression by observing the ratios
of responders to Tregs. Ratios of dilution enable study of dose-
dependence. All groups of Tregs displayed suppressive function on
CD81 T cells, but the degree varied by treatment group (Fig. 5a, left
panel). TNFR2 agonist-treated Tregs, for example, showed the
strongest suppressive capacity at 151 ratio (by leaving the fewest
number of CD81 cells) and then became progressively weaker at
higherratios.However,theantagonist-treatedcellsdisplayedweaker
suppressive capacity that was essentially no different from that of
standard treatment. At a suppression index of 251, the TNFR2
agonist-treated group showed greater suppression than did the
antagonist and standard treatment groups (Fig. 5a, right panel).
Similar results were observed with Tregs treated without rapamycin
(Supplementary Fig. 7a). The results are consistent with known
phenotypes and expansion capacity of functional Tregs.
TNFR2 agonist-treated Tregs and cytokine production. We found
that all treatment groups had relatively limited ability to produce
intracellular IFNc and IL-10 after PMA and ionomycin stimula-
tion. But TNFR2 agonist and the TNF only-treated Tregs produced
thelowestpercentagesofIFNc1cells(Fig.5b,lowestleftpanel).The
antagonist-treated Tregs showed significantly higher IFNc
production than the agonist (Fig. 5b, lower left panel). In similar
experiments without rapamycin, the TNFR2 agonist-treated group
not only produced lower IFNc, but also lower IL-10 and TNF
production relative to TNF or standard treatment, respectively
(Supplementary Fig. 7b). Agonist-treated Tregs also showed the
www.nature.com/scientificreports
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which is consistent with lower IFNc production (Fig. 5c). One of the
reasons for these Tregs showing high suppression capacity over CD8
T cells may be due to Tregs lacking the ability to produce IFNc.
Clinical trial induction of human Tregs. We sought to determine in
ahumanclinicaltrialwhetherTNFtriggersTregexpansion.Thistrial
was important because the human literature holds contradictory
evidence
33. Because an FDA-approved version of TNF does not
exist and manufacturing of a stable human form of TNF is diffi-
cult, we administered a well-known, strong inducer of naturally
secreted TNF, Bacillus Calmette Gue ´rin (BCG). BCG is a generic
vaccine already on the market for decades for treating tuberculosis
andbladdercancer.Indiverseanimalmodelsofautoimmunity,BCG
or CFA (the equivalent of BCG but not manufactured under cGMP
conditions) can induce Tregs and can eliminate autoimmunity. TNF
induction is solely responsible for these beneficial effects, because
they can be eliminated by anti-TNF antibodies
40,41.
The small proof-of-principle, double-blind placebo-controlled
clinical trial enrolled two human subjects. One subject received
repeat BCG injections (1.6–3.2 3 10
6 cfu/injection) and one placebo
subject received repeat saline, twice, 4-weeks apart. Both were mon-
itored weekly for 20-weeks to study the pharmacokinetics of TNF
andTreginduction.AftereachBCGinjection,TNFinducedTregsina
bi-modal fashion with slightly delayed kinetics (Fig. 6a, left panels).
After 20weeks of observation, saline injections induced neither TNF
nor Tregs (Fig. 6b, center panels). The total CD41 cell counts didnot
change in the BCG and placebo patients other than in the percen-
tages of CD4 1 CD25
hiFOXP31 cells (data not shown). Because
TNF is not the only cytokine stimulated by BCG injection, we also
sought to determine whether TNF was necessary and sufficient for
inductionofTregs.Duringroutinecare,arheumatoidarthritissubject
on Enbrel (etanercept), an anti-TNF antibody, was administered a
BCGvaccineforprotectionfromtuberculosis.Thesametightweekly
TNF and Treg monitoring revealed that Enbrel blocked both endo-
genoussecretionofTNFandinductionofTregs(Fig.6c,rightpanels).
This in vivo evidence supports endogenous TNF as being obligatory
for Treg induction in humans.
Discussion
We have developed a new method, acting through the TNF and
especially the TNFR2 receptor, to obtain ex vivo an expanded and
homogeneous populations of human Tregs. We identified a novel
TNFR2 agonist that, combined with four standard Treg expansion
protocols,IL-2,anti-CD3,anti-CD3andanti-CD28(withorwithout
rapamyacin), produces phenotypically homogeneous Tregs. These
homogeneous Tregs also have greater capacity to suppress cytotoxic
T lymphocytes than does standard treatment. The expanded Tregs
bore the near homogeneous phenotype CD4
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Figure 5 | Functional assays of Tregs expanded under four treatment conditions. (a) In a representative case, TNFR2 agonist-treated Tregs exerted
stronger and dose-dependent suppression of CD81 cell numbers, compared to other groups, at all dilutions or suppression ratios (left panel, third
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2. The TNFR2-expanded Tregs did not
release significant quantities of cytokines IFNc and IL-10. We also
show that Tregs could also be selectively inhibited by a different
TNFR2 antibody, an antagonist. The evidence builds the case for
TNFR2 as a strong molecular target with the capacity to exert bi-
directional control over humans Tregs (Fig. 6d).
Tregsareexpandedinexvivoprotocolsbecausethestandardagents
commonly used for their expansion, including IL-2, anti-CD3 and
anti-CD28, are systemically toxic. But we have also shown, through
our Phase I randomized clinical trial, that a TNF-inducer, BCG,
produces a surge of endogenous TNF followed by proliferation of
Tregs
45. BCG is a safe vaccine that has been used for more than 80
yearstocombattuberculosis.Thisinvivohumanstudydemonstrates
the expansion of Tregs with endogenously synthesized TNF. The
tantalizing prospect of eventually expanding Tregs in vivo is sup-
ported by the findings that TNFR2 has limited cellular distribution,
and TNFR2-specific ligands are not systemically toxic in a baboon
study
36.
Certain findings stand out, particularly the dose-dependent sup-
pression of cytotoxic CD81 T cells elicited by the TNFR2 agonist
expansion of Tregs. Dose-dependency has the potential to modulate
the actions of Tregs on these pivotal target cells that are lethal to
other cell types. This is an attractive feature in terms of CD81 cell
targeting. Remarkably the opposing functions resulting from anti-
body binding to the same cell surface receptor were mediated by
divergent intracellular signaling events. The TNFR2 agonist stimu-
lated intracellular expression of important mRNAs such as TRAF2,
BIRC3 (cIAP2), CHUK and FOXP3. In contrast, the TNFR2 ant-
agonist did not stimulate intracellular expression of TRAF2, TRAF3
or FOXP3 (Fig. 2c, Fig. S2b). The normal function of the CHUK
gene, part of the IKK complex, is to activate NFkB. TRAF2, also
stimulated bythe TNFR2 agonist, is also required for TNF-mediated
activation of NFkB and the MAPK8/JNK pathway which associates
with cIAP2. Therefore this signaling data is consistent with our
characterization of the same receptor have opposing intracellular
regulation that can beactivated bytwofunctionallyopposing mono-
clonal antibodies.
It is remarkable how consistently the mouse literature shows TNF
induction of Tregs whereas the human literature is conflicting
33,46,47.
Indeed TNF is a difficult cytokine to manufacture. The fact that we
have identified monoclonal antibodies with preferential signaling
throughtheTNFR2receptorisadvantageousbecausemanufacturing
antibodiesisfareasierthanmanufacturingcytokines.Whatisnotyet
knownabouthumantranslationalexperimentsusingexpanded Tregs
incultureistheirstability,durabilityandmigratoryactivitiesleading
to important clinical effects. Interestingly in our presented pilot trial
andpasttrials,theinductionofsystemicTNFwasfollowedbyabrief
one week long induction of Tregs that had functional properties in
suppressing autoimmunity for weeks so the immunoregulation of
Tregs may not directly correspond to the life of the cell (Fig. 6a)
45.
With properly conducted human trials, the careful dosing of these
cells can be linked to the above properties
48.
Taken together, this study provides the rationale for TNFR2 as
a potentially attractive molecular target for in vivo and ex vivo
treatment of diverse diseases in which Tregs play important roles.
This single receptor has bi-directional control over Tregs, i.e., dif-
ferent antibody ligands can act as agonists or antagonists over one
receptor. Our evidence confirms that TNFR2 is highly and pref-
erentially expressed on Tregs with the purer CD4 1 CD25
hiFOXP3
phenotype expressing the highest density of TNFR2
47. Our find-
ings suggest that agonist and antagonist ligands aimed at a single
receptor, TNFR2, hold the potential for selectively turning on or
turning off Tregs for diseases as diverse as allergy, autoimmunity,
cancer, transplantation, graft versus host disease (GVHD) and
infectious disease.
Methods
HumansubjectsandTNFinductionwithBCGvaccine.Over500individualhuman
blood specimens served as normal blood lymphocytes for these studies through a
human studies protocol approved by the Massachusetts General Hospital Human
Studies Committee (MGH-2001P001379). This approval involves the obligatory
informed consent for all subjects. All blood was drawn and processed within 2 hours
so that the isolated human T cells were fresh and not altered by transport or storage
conditions. The T cells isolated from fresh human blood were used both for the Treg
assays, as well as for identification and screening of new and commercially available
monoclonal antibodies to the TNF receptor.
For the interventional trial and the observational study, either one or two BCG
vaccinations were used to induce TNF. Administration of two BCG vaccinations was
approved by the Human Studies Committee at Massachusetts General Hospital and
by the FDA (NCT00607230). Both oversight and approval committees require full
informed consent from all participants. For the single BCG vaccination subject, the
vaccine was administered during routine care for a travel indication in a subject that
was on chronic Enbrel for her long-standing rheumatoid arthritis. The blood was
drawn according to our standard protocol listed above.
For the double-blinded placebo-controlled trial with multi-dosing of BCG, one
subjectwasinjectedwithBCGatadoseof1.6–3.2310
6 cfuontwooccasionsandthe
placebosubjectwasinjectedwithsalineontwooccasions.TheBCGorsalineinjection
was administered intradermally four-weeks apart. All blood samples were blinded
and simultaneously sent to the laboratory for monitoring TNF and Treg levels.
Reagents and flow cytometry. Recombinant human TNF was purchased from
Leinco Technologies (St. Louis, MO), and recombinant human IL-2 was purchased
from Sigma-Aldrich (St. Louis, MO). Human monoclonal antibodies against
TNFR1 and TNFR2 were from internal sources (produced through immunizations
of TNFR22/2 mice and Balb/c mice with recombinant external TNFR2
membrane proteins (Recombinant Human TNF RII/TNFRSF1B, aa 24–206, R&D
Systems) and external commercial vendors. External vendors included R&D
Systems, Hycult- Biotechnology, BD-Pharmingen, Accurate, Abcam and Sigma for
the purchase of commercially available anti-human TNFR1/2 antibodies. For the
characterization of monoclonal antibodies binding to the TNFR1/2, the majority of
the monoclonal antibodies bound to the receptor but neither signaled nor acted as
an agonist or antagonist in functional assays (Supplementary Fig. 1). The best
agonist and the best antagonist TNFR2 antibody were brought forward for study.
All other antibodies to other cell surface receptors were purchased from BD-
Biosciences. Intracellular staining of FOXP3 and CD152 were performed using
either FOXP3 Fix/Perm Buffer set (Biolegend) or Human FOXP3 Buffer set (BD
Biosciences).
Four methods of CD4
1CD25
1 expansion with TNF, TNFR2 monoclonal
antibodies. To test various human-directed TNFR2 monoclonal antibodies for
functional and expansion effects on fresh human CD4 T cells, four previously
published functional assays for in vitro expansion of Tregs were tested
4,16,48,49. These
four expansion protocols were combined with and without the presence of various
TNF receptor reagents, including TNF itself and monoclonal antibodies directed to
TNFR1/2. While most of the TNFR2 directed monoclonal antibodies had no effects
onTregs,twowerebrought forward forintensivestudy because theyeitherinducedor
suppressed Tregs.
First, CD41 T cells were cultured with IL-2 and various TNF reagents. Second,
CD41T cells were cultured with anti-CD3 antibodies and the various TNF reagents.
Third, CD41 CD251 T were cultured with anti-CD3 and anti-CD28 and various
TNF reagents and lastly, CD41CD251 T were cultured with anti-CD3 and anti-
CD28 and rapamycin.
CD41 T cells were isolated using Dynal CD4 Positive Isolation Kit (Invitrogen).
Extraction of CD25 positive cells were subsequently performed after CD41 isolation
using Dynabeads CD25 and DETACHaBEAD CD4/CD8 (Invitrogen). After isola-
tion, 2 3 10
4 cells were cultured in 96-round-bottom well plate. Dynabeads for
human Treg Expander (Invitrogen) was added at a beads-to-cell ratio of 251. In
selected wells, TNF (20 ng/ml), TNFR1 or TNFR2 mAbs (2.5 mg/ml), rapamycin
(1 mM, EMD Biosciences, San Diego, CA) was added. After two days, IL-2 (200 U/
ml) was added to the culture. Half of the media was changed every 2 to 3 days
containing rapamycin (until day 7) and 100 U/ml of IL-2. On day 9, additional TNF
or TNFR2 mAbs were supplied into the media. On day 16, cells were harvested,
DynabeadsHumanTregExpanderwasremoved,washedandrested.Onthefollowing
day, cells were analyzed.
Intracellular staining. Expanded CD4
1CD25
1 cells were stimulated with phorbol
myristate acetate (PMA) (2 ng/ml) and ionomycin (500 ng/ml) (Sigma) for
24 hours. Monensin (GolgiStop, BD Biosciences) was added for the last 4 hours of
incubation. Cells were fixed and permeabilized using Human FOXP3 Buffer Set,
followed by staining with fluorochrome-conjugated IFNc and IL-10 mAbs.
mRNA isolation. Isolated CD41 cells were incubated in the presence of IL-2 (50 U/
ml)withorwithoutTNFR2mAbs(2.5 mg/ml).After3 hours,cellswerecollectedand
total RNA was isolated using RNAqueous-4PCR kit (Ambion, Austin, TX). The
extracted RNA was reverse transcribed using High Capacity cDNA Reverse
Transcription Kit (Applied-Biosystems, Foster City, CA).
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CD41 cells were stained with 1 mM carboxyfluorescein diacetate succinimidyl ester
(CFSE).Cellswereplatedatthedensityof2310
5 cells/wellin96-wellplatewithanti-
CD3mAbs. Four days later, cells were collected and analyzed.
For Treg suppression assay, autologous PBMCs were used as responders. PBMC
were collected using Ficoll-Paque, cryopreserved at 280uC, and thawed at the day
before mixed with Tregs and rested overnight in RPMI 1640 and 10 U/ml IL-2. The
next day, responder cells were stained with CFSE (1 mM). Responder cells (5 3 10
4
cells) and expanded Tregs were mixed at various ratios, and stimulated with anti-
CD3mAb and IL-2. After 4 days, cells were collected and analyzed.
Statistical analysis. All data analyses were performed by the paired Student t test
usingGraphPadPrism-5software(GraphPadSoftware,LaJolla,CA).Weconsidered
two-sided p value 0.05 as significant.
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